MCMaría De la Calle

María De la Calle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


María De la Calle has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Antonio De la Vieja

    Tumor Endocrine Unit, Chronic Disease Program (UFIEC), Instituto de Salud Carlos III (ISCIII), Ctra. Majadahonda-Pozuelo Km. 2,2., Majadahonda, Madrid 28220, Spain

    1 shared publication
  • Custodia García-Jiménez

    Area of Physiology, Faculty Health Sciences, University Rey Juan Carlos, 28922, Alcorcón, Madrid, Spain.

    1 shared publication
  • Jose Carlos Moreno

    Thyroid Molecular Laboratory, Institute for Medical and Molecular Genetics (INGEMM), La Paz University Hospital Research Institute (IdiPAZ), Autonomous University of Madrid, Madrid, Spain

    1 shared publication
  • Maddi Garate-Etxeberria

    Tumor Endocrine Unit, Chronic Disease Program (UFIEC), Instituto de Salud Carlos III, Ctra. Majadahonda a Pozuelo km 2.2, 28220 Madrid, Spain

    1 shared publication
  • MariPaz López-Molina

    Neurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Hospital La Paz Institute for Health Research IdiPAZ, La Paz University Hospital, Universidad Autónoma de Madrid, 28046 Madrid, Spain

    1 shared publication
  • Pouya Alikhani

    Thyroid Molecular Laboratory, Institute for Medical and Molecular Genetics (INGEMM), La Paz University Hospital Research Institute (IdiPAZ), 28029 Madrid, Spain

    1 shared publication

Latest Publications

  • Open Access

    New Insights into Iodide Transport Defects (ITDs) from the Characterization of a Heterozygous NIS Missense Variant (p.G288S) Identified in a Family with Thyroid Dysfunction During Pregnancy

    by Maddi Garate-Etxeberria, Mari Paz Lopez-Molina, Rafael Hortiguela, Pouya Alikhani, María De la Calle, Custodia García-Jimenez, Jose Carlos Moreno, Antonio De la Vieja

    The Na+/I− symporter (NIS) is the plasma membrane (PM) protein that actively mediates iodide (I−) transport into the thyroid gland. Pathogenic variants in the SLC5A5 gene cause iodide transport defects (ITDs). A heterozygous G288S NIS variant was identified in a Spanish family in which female carriers developed thyroid dysfunction during pregnancy. Here, we characterized the functional significance of the G288S variant and other substitutions at residue 288 of human NIS. Human NIS (hNIS) expression and maturation were analyzed by immunoblotting, its subcellular localization was analyzed by immunofluorescence and flow cytometry, and its activity was analyzed by radioiodide uptake assays. The G288S variant does not affect hNIS maturation, membrane trafficking, or I− uptake capacity, but significantly reduces I− affinity while preserving substantial transport activity. In contrast, substitutions introducing charged residues (arginine, aspartic acid, or glutamic acid) or proline severely disrupted NIS maturation, plasma membrane targeting, and iodide transport. Because the variant was identified in heterozygosity, we evaluated residue 288 substitutions under heterozygous-like conditions. Co-expression of the patient-derived G288S variant with WT NIS produced an intermediate apparent Km without reducing Vmax compared with WT, consistent with a modest co-expression-dependent kinetic effect rather than a strong dominant-negative mechanism. In contrast, the severely disruptive G288E substitution reduced cell-surface NIS expression under co-expression conditions, providing proof-of-principle evidence that severe alteration of residue 288 can impair NIS plasma membrane delivery. These findings highlight residue 288 as a key determinant of hNIS functionality and underscore the need to carefully evaluate heterozygous SLC5A5/NIS variants, as they may become clinically relevant under conditions of increased physiological iodine demand and contribute to partial iodide transport impairment.